Abstract
A high-yielding protocol for atropisomeric resolution was developed by rectifying inherent incompatibilities between crystallization and epimerization via continuous processing. Application toward synthesis of MRTX1719, a densely functionalized active pharmaceutical ingredient (API), improved yield from 37% to 87%. This protocol provides a complementary means to access rotamers which challenge current asymmetric methodologies, and greatly improves sustainability by decreasing consumption of solvent and advanced synthetic intermediates.
Supplementary materials
Title
Supporting information
Description
Experimentals and data for publication
Actions